-+ 0.00%
-+ 0.00%
-+ 0.00%

According to Zhitong Finance App, China Resources Pharmaceutical (03320.HK) announced that on July 21, 2026, China Resources Pharmaceutical Holdings Co., Ltd. (China Resources Pharmaceutical Holdings), a wholly-owned subsidiary of the Company, has completed issuing the first issue of 2026 medium-term notes (the first 2026 medium-term note) in China. The first 2026 medium-term note with a principal amount of RMB 1 billion has been issued. The term is three years, and the coupon interest rate is 1.53% per annum. The funds raised from the issuance of the first 2026 medium-term notes will be used to supplement working capital, repay interest-bearing debts, and other purposes in accordance with applicable laws and regulations.

Zhitongcaijing·07/22/2026 10:09:08
Listen to the news
According to Zhitong Finance App, China Resources Pharmaceutical (03320.HK) announced that on July 21, 2026, China Resources Pharmaceutical Holdings Co., Ltd. (China Resources Pharmaceutical Holdings), a wholly-owned subsidiary of the Company, has completed issuing the first issue of 2026 medium-term notes (the first 2026 medium-term note) in China. The first 2026 medium-term note with a principal amount of RMB 1 billion has been issued. The term is three years, and the coupon interest rate is 1.53% per annum. The funds raised from the issuance of the first 2026 medium-term notes will be used to supplement working capital, repay interest-bearing debts, and other purposes in accordance with applicable laws and regulations.